Cytek Biosciences Inc. (CTKB)

NasdaqGS: CTKB · Real-Time Price · USD

4.75

-0.14 (-2.86%)

At close: Aug 14, 2026, 2:57 PM

Statistics

Share Statistics

Cytek Biosciences has 129.98M shares outstanding. The shares have a market value of 617.42M.

Shares Outstanding	129.98M
Shares Change (YoY)	-2.19%
Shares Change (QoQ)	0.59%
Owned by Institutions (%)	58.51%
Shares Floating	95.53M
Failed to Deliver (FTD) Shares	82
FTD / Avg. Volume	n/a

Short Selling Information

Short interest in Cytek Biosciences is 3.77% of the outstanding shares, representing 4.9M shares. The short ratio is 6.09.

Short Interest	4.9M
Short % of Shares Out	3.77%
Short % of Float	4.76%
Short Ratio (days to cover)	6.09

Valuation Ratios

PE Ratio	n/a
Forward PE	67.86
PS Ratio	2.99
Forward PS	2.77
PB Ratio	1.92
P/FCF Ratio	-50.73
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The enterprise value is 400.07M. Enterprise value adds debt and subtracts cash from the company's market cap, providing an alternative valuation for the company.

EV / Sales	1.94
EV / EBITDA	-10.06
EV / EBIT	-66.26
EV / FCF	-32.87

Financial Position

Cytek Biosciences's current ratio is 4.48. A current ratio above 1 means that the company has enough short-term assets to cover its short-term liabilities.

Current Ratio	4.48
Quick Ratio	3.71
Debt / Equity	0.08
Debt / EBITDA	-0.93
Debt / FCF	-2.17
Interest Coverage	-129.82

Financial Efficiency

Return on Equity is -23.04%, and return on invested capital is -11.63%.

Return on Equity	-23.04%
Return on Assets	-6.31%
Return on Invested Capital	-11.63%
Revenue Per Employee	$303.09K
Profits Per Employee	$-118.15K
Employee Count	682
Asset Turnover	0.46
Inventory Turnover	1.85

Taxes

Income Tax	39.76M
Effective Tax Rate	-97.42%

Stock Price Statistics

The stock price has increased by 21.95% in the past year.

Beta	1.17
52-Week Price Change	21.95%
50-Day Moving Average	4.36
200-Day Moving Average	4.59
Relative Strength Index (RSI)	66.41
Average Volume (20 Days)	1,362,580

Income Statement

In the last 12 months, Cytek Biosciences had revenue of 206.71M and earned -80.58M in profits. Earnings per share was -0.63.

Revenue	206.71M
Gross Profit	110.03M
Operating Income	-44.65M
Net Income	-80.58M
EBITDA	-28.6M
EBIT	-40.5M
Earnings Per Share (EPS)	-0.63

Full Income Statement

Balance Sheet

Cytek Biosciences has 73.85M in cash on the balance sheet. Total assets are 446.93M, and total liabilities are 26.46M.

Cash & Cash Equivalents	73.85M
Total Debt	26.46M
Net Cash	47.39M
Retained Earnings	-132.76M
Total Assets	446.93M
Working Capital	293.6M

Full Balance Sheet

Cash Flow

Cytek Biosciences's operating cash flow was -6.04M over the trailing twelve months.

Operating Cash Flow	-6.04M
Capital Expenditures	-6.13M
Free Cash Flow	-12.17M
FCF Per Share	-0.094

Full Cash Flow Statement

Margins

Cytek Biosciences's gross profit margin was 53.23%, while its operating and net profit margins were -21.6% and -38.98%, respectively.

Gross Margin	53.23%
Operating Margin	-21.6%
Pretax Margin	-19.75%
Profit Margin	-38.98%
EBITDA Margin	-13.84%
EBIT Margin	-19.59%
FCF Margin	-5.89%

Dividends & Yields

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	0%
Earnings Yield	-13.26%
FCF Yield	-1.97%

Dividend Details

Analyst Forecast

According to 4 stock analysts, the average 12-month price target for Cytek Biosciences is $5. The average analyst rating is "Buy".

Price Target	$5
Price Target Difference	5.26%
Analyst Consensus	Buy
Analyst Count	4

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the fair value of a stock, including the Graham Number and Lynch Fair Value methods.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	3.5
Piotroski F-Score	4